what are the negative effects of bpc 157 BPC-157: Tendon Repair and More Potential Side Effects of BPC-157

Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026

The peptide's actin-sequestering activity enables the rapid cytoskeletal reorganization required for keratinocyte migration and fibroblast movement into wound sites, with studies showing 2-3 fold increases in migration rates and improved directional persistence compared to untreated controls

By working closely with Tricare-authorized healthcare providers, adhering to eligibility criteria, and maintaining open communication with the program, individuals can take steps toward achieving their weight loss goals and improving their overall health.

What if BPC-157 doesn't help my GLP-1 side effects